Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong Ben

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Plos One|April 28, 2020
Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapyMagdalena Zajac, Jiabu Ye, Pralay Mukhopadhyay, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial CarcinomaYanan Zheng, Rajesh Narwal, ChaoYu Jin, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusPaul G Baverel, Vincent F S Dubois, Chao Yu Jin, et al.
AI Zheng = Aizheng = Chinese Journal of Cancer|September 13, 2006
[Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]Fang Hu, Xiao-Hua Hu, Ping Yu, et al.
Archives of Pathology & Laboratory Medicine|November 21, 2018
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial CarcinomaMagdalena Zajac, Anne-Marie Boothman, Yong Ben, et al.
JAMA Oncology|August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label StudyThomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Plos One|April 28, 2020
Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapyMagdalena Zajac, Jiabu Ye, Pralay Mukhopadhyay, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial CarcinomaYanan Zheng, Rajesh Narwal, ChaoYu Jin, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusPaul G Baverel, Vincent F S Dubois, Chao Yu Jin, et al.
AI Zheng = Aizheng = Chinese Journal of Cancer|September 13, 2006
[Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]Fang Hu, Xiao-Hua Hu, Ping Yu, et al.
Archives of Pathology & Laboratory Medicine|November 21, 2018
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial CarcinomaMagdalena Zajac, Anne-Marie Boothman, Yong Ben, et al.
JAMA Oncology|August 18, 2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label StudyThomas Powles, Peter H O'Donnell, Christophe Massard, et al.
Pageof 2